Your browser is no longer supported. Please, upgrade your browser.
NVAX [NASD]
Novavax, Inc.
Index- P/E- EPS (ttm)-14.82 Insider Own0.30% Shs Outstand75.61M Perf Week-21.57%
Market Cap6.23B Forward P/E2.90 EPS next Y26.58 Insider Trans-56.69% Shs Float75.21M Perf Month-56.44%
Income-1075.00M PEG- EPS next Q-0.40 Inst Own50.30% Short Float11.87% Perf Quarter-42.96%
Sales1.20B P/S5.18 EPS this Y-32.00% Inst Trans0.03% Short Ratio1.46 Perf Half Y-56.87%
Book/sh6.17 P/B12.51 EPS next Y315.90% ROA-45.20% Target Price250.00 Perf Year-39.28%
Cash/sh24.00 P/C3.22 EPS next 5Y0.00% ROE-149.70% 52W Range66.38 - 331.68 Perf YTD-46.03%
Dividend- P/FCF13.74 EPS past 5Y9.50% ROI-38.00% 52W High-76.72% Beta1.38
Dividend %- Quick Ratio1.20 Sales past 5Y67.30% Gross Margin- 52W Low16.32% ATR14.44
Employees791 Current Ratio1.20 Sales Q/Q13.90% Oper. Margin-86.80% RSI (14)23.07 Volatility13.75% 11.01%
OptionableYes Debt/Eq0.93 EPS Q/Q-34.60% Profit Margin-89.30% Rel Volume1.23 Prev Close79.47
ShortableYes LT Debt/Eq0.70 EarningsNov 04 AMC Payout- Avg Volume6.11M Price77.21
Recom2.30 SMA20-37.76% SMA50-51.79% SMA200-58.59% Volume7,483,488 Change-2.84%
Jan-21-22Initiated Cowen Outperform $150
May-12-21Downgrade JP Morgan Overweight → Neutral $285 → $161
Dec-14-20Initiated Jefferies Buy $200
Aug-06-20Reiterated H.C. Wainwright Buy $132 → $290
Aug-05-20Upgrade JP Morgan Neutral → Overweight $275
Aug-05-20Downgrade Ladenburg Thalmann Neutral → Sell $105
Jul-16-20Reiterated H.C. Wainwright Buy $101 → $132
Jul-08-20Downgrade Ladenburg Thalmann Buy → Neutral $50 → $105
Jun-29-20Reiterated H.C. Wainwright Buy $50 → $101
Jun-29-20Reiterated B. Riley FBR Buy $74 → $106
Jun-05-20Upgrade JP Morgan Underweight → Neutral $46
May-28-20Reiterated B. Riley FBR Buy $53 → $61
May-12-20Reiterated H.C. Wainwright Buy $33 → $50
Apr-30-20Reiterated H.C. Wainwright Buy $24 → $33
Nov-27-19Resumed B. Riley FBR Buy $12
Aug-14-19Reiterated H.C. Wainwright Buy $10 → $17
Feb-28-19Downgrade Piper Jaffray Overweight → Underweight $4.50 → $0.25
Dec-18-18Initiated Ladenburg Thalmann Buy $3
Dec-11-18Initiated Oppenheimer Outperform $4
Nov-26-18Upgrade Piper Jaffray Neutral → Overweight
Jan-25-22 04:43PM  
08:05AM  
05:06AM  
04:31AM  
Jan-24-22 06:37PM  
02:48PM  
Jan-23-22 06:00AM  
Jan-21-22 05:38PM  
03:47PM  
01:59PM  
01:47PM  
11:15AM  
09:38AM  
09:38AM  
Jan-20-22 05:35PM  
05:14PM  
04:59PM  
04:35PM  
03:43PM  
12:33PM  
Jan-19-22 06:21PM  
04:03PM  
06:30AM  
Jan-18-22 03:19PM  
07:42AM  
05:06AM  
Jan-17-22 09:30AM  
Jan-16-22 07:01AM  
Jan-14-22 05:38PM  
03:35PM  
01:39PM  
11:02AM  
08:16AM  
06:00AM  
03:30AM  
Jan-13-22 02:19PM  
01:52PM  
06:30AM  
Jan-12-22 05:45PM  
03:35PM  
02:56PM  
11:10AM  
10:40AM  
08:28AM  
07:43AM  
06:15AM  
06:10AM  
06:04AM  
06:00AM  
03:00AM  
Jan-11-22 11:56PM  
03:33PM  
01:22PM  
Jan-10-22 05:51PM  
03:37PM  
02:52PM  
08:39AM  
Jan-07-22 04:45PM  
04:26PM  
01:55PM  
01:37PM  
01:25PM  
11:25AM  
05:53AM  
Jan-06-22 04:31PM  
Jan-05-22 06:05PM  
04:22PM  
06:00AM  
Jan-04-22 04:35PM  
04:02PM  
11:59AM  
11:56AM  
06:26AM  
06:08AM  
05:58AM  
Jan-03-22 04:52PM  
11:42AM  
11:39AM  
10:49AM  
10:24AM  
08:22AM  
05:19AM  
05:06AM  
Jan-01-22 06:45AM  
Dec-31-21 07:37PM  
02:50PM  
01:47PM  
01:04PM  
12:38PM  
12:15PM  
08:52AM  
08:45AM  
08:27AM  
05:06AM  
Dec-30-21 10:12PM  
03:40PM  
02:54PM  
01:00PM  
11:35AM  
11:00AM  
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. In addition, the company develops vaccine candidates for the protection against middle east respiratory syndrome, as well as that is in preclinical work associated with severe acute respiratory syndrome; and ebola virus glycoprotein vaccine candidate, as well as COVID-19 vaccine for variant strain. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Herrmann John A IIIEVP, Chief Legal OfficerJan 03Option Exercise19.085,00095,4008,845Jan 05 05:22 PM
Herrmann John A IIIEVP, Chief Legal OfficerJan 03Sale140.915,000704,5343,845Jan 05 05:22 PM
YOUNG JAMES FDirectorDec 31Option Exercise25.603,75096,00078,840Jan 04 05:04 PM
YOUNG JAMES FDirectorDec 31Sale144.163,750540,60175,090Jan 04 05:04 PM
Herrmann John A IIIEVP, Chief Legal OfficerDec 20Option Exercise19.085,00095,4008,845Dec 22 05:03 PM
Herrmann John A IIIEVP, Chief Legal OfficerDec 20Sale230.005,0001,150,0003,845Dec 22 05:03 PM
Glenn Gregory MPresident, R&DDec 15Option Exercise34.821,68658,7147,349Dec 16 05:15 PM
Glenn Gregory MPresident, R&DDec 15Sale174.131,686293,5845,663Dec 16 05:15 PM
DOUGLAS RICHARDDirectorDec 13Option Exercise25.601,50038,40033,450Dec 15 05:22 PM
Glenn Gregory MPresident, R&DDec 07Option Exercise19.088,250157,41012,311Dec 09 05:20 PM
Glenn Gregory MPresident, R&DDec 07Sale170.148,2501,403,6314,061Dec 09 05:20 PM
Herrmann John A IIIEVP, Chief Legal OfficerDec 01Option Exercise19.085,00095,4007,760Dec 03 06:30 PM
Herrmann John A IIIEVP, Chief Legal OfficerDec 01Sale196.195,000980,9442,760Dec 03 06:30 PM
Glenn Gregory MPresident, R&DNov 30Option Exercise19.088,250157,41013,003Dec 02 04:13 PM
Glenn Gregory MPresident, R&DNov 30Sale203.208,9421,817,0004,061Dec 02 04:13 PM
Herrmann John A IIIEVP, Chief Legal OfficerNov 29Option Exercise19.085,00095,4007,760Dec 01 05:02 PM
Herrmann John A IIIEVP, Chief Legal OfficerNov 29Sale228.725,0001,143,6002,760Dec 01 05:02 PM
Glenn Gregory MPresident, R&DNov 26Option Exercise5.953,46020,5876,144Nov 30 05:06 PM
Glenn Gregory MPresident, R&DNov 26Sale218.072,083454,2474,061Nov 30 05:06 PM
Glenn Gregory MPresident, R&DNov 23Option Exercise19.088,250157,41012,311Nov 24 05:21 PM
Glenn Gregory MPresident, R&DNov 23Sale199.508,2501,645,9144,061Nov 24 05:21 PM
Glenn Gregory MPresident, R&DNov 16Option Exercise19.088,250157,41012,311Nov 17 05:25 PM
Glenn Gregory MPresident, R&DNov 16Sale169.488,2501,398,1804,061Nov 17 05:25 PM
Glenn Gregory MPresident, R&DNov 15Option Exercise37.901,18344,8325,244Nov 17 05:25 PM
Glenn Gregory MPresident, R&DNov 15Sale172.021,183203,4964,061Nov 17 05:25 PM
Glenn Gregory MPresident, R&DNov 09Option Exercise19.088,250157,41012,311Nov 12 05:02 PM
Glenn Gregory MPresident, R&DNov 09Sale167.538,2501,382,1604,061Nov 12 05:02 PM
Herrmann John A IIIEVP, Chief Legal OfficerNov 03Option Exercise19.085,00095,4007,760Nov 05 05:02 PM
Herrmann John A IIIEVP, Chief Legal OfficerNov 03Sale200.005,0001,000,0002,760Nov 05 05:02 PM
Glenn Gregory MPresident, R&DNov 02Option Exercise19.088,250157,41012,311Nov 04 05:22 PM
Glenn Gregory MPresident, R&DNov 02Sale183.828,2501,516,5524,061Nov 04 05:22 PM
Herrmann John A IIIEVP, Chief Legal OfficerNov 01Option Exercise19.085,00095,4007,760Nov 03 04:49 PM
Herrmann John A IIIEVP, Chief Legal OfficerNov 01Sale163.085,000815,4222,760Nov 03 04:49 PM
Glenn Gregory MPresident, R&DOct 29Sale148.34680100,8714,061Nov 02 07:02 PM
Glenn Gregory MPresident, R&DOct 26Option Exercise15.2011,712178,00914,395Oct 28 05:09 PM
Glenn Gregory MPresident, R&DOct 26Sale132.7310,3341,371,6674,061Oct 28 05:09 PM
Glenn Gregory MPresident, R&DOct 19Option Exercise19.088,250157,41012,311Oct 21 05:08 PM
Glenn Gregory MPresident, R&DOct 19Sale165.148,2501,362,4274,061Oct 21 05:08 PM
Glenn Gregory MPresident, R&DOct 15Option Exercise37.901,18344,8325,244Oct 19 05:04 PM
Glenn Gregory MPresident, R&DOct 15Sale170.001,183201,1104,061Oct 19 05:04 PM
Glenn Gregory MPresident, R&DOct 12Option Exercise19.088,250157,41012,311Oct 14 05:16 PM
Glenn Gregory MPresident, R&DOct 12Sale163.188,2501,346,2184,061Oct 14 05:16 PM
Glenn Gregory MPresident, R&DOct 05Option Exercise19.088,250157,41012,311Oct 07 05:18 PM
Glenn Gregory MPresident, R&DOct 05Sale174.418,2501,438,8954,061Oct 07 05:18 PM
Erck Stanley CPresident and CEOOct 04Option Exercise27.4542,8291,175,58366,708Oct 05 05:05 PM
Erck Stanley CPresident and CEOOct 04Sale176.1542,8297,544,19523,879Oct 05 05:05 PM
Herrmann John A IIIEVP, Chief Legal OfficerOct 01Option Exercise19.085,00095,4007,760Oct 05 05:02 PM
Erck Stanley CPresident and CEOOct 01Option Exercise27.1749,0001,331,40072,879Oct 05 05:04 PM
Erck Stanley CPresident and CEOOct 01Sale175.1049,0008,580,06423,879Oct 05 05:04 PM
Herrmann John A IIIEVP, Chief Legal OfficerOct 01Sale174.895,000874,4522,760Oct 05 05:02 PM
Glenn Gregory MPresident, R&DSep 30Sale207.25693143,6224,061Oct 01 05:58 PM
Trizzino JohnEVP, CCO and CBOSep 28Option Exercise19.087,501143,11910,047Sep 29 05:06 PM
Trizzino JohnEVP, CCO and CBOSep 28Sale209.927,5011,574,6372,546Sep 29 05:06 PM
Trizzino JohnEVP, CCO and CBOSep 27Option Exercise19.087,501143,11910,047Sep 29 05:04 PM
Glenn Gregory MPresident, R&DSep 27Option Exercise5.953,46020,5876,144Sep 29 05:08 PM
Glenn Gregory MPresident, R&DSep 27Sale234.432,083488,3154,061Sep 29 05:08 PM
Trizzino JohnEVP, CCO and CBOSep 27Sale234.617,5011,759,8332,546Sep 29 05:04 PM
MOTT DAVID MDirectorSep 23Sale252.9024,9616,312,61640,000Sep 24 05:10 PM
Trizzino JohnEVP, CCO and CBOSep 21Option Exercise19.087,500143,1008,218Sep 22 05:05 PM
Trizzino JohnEVP, CCO and CBOSep 21Sale227.377,5001,705,265718Sep 22 05:05 PM
Trizzino JohnEVP, CCO and CBOSep 20Option Exercise19.087,500143,1008,218Sep 22 05:05 PM
Trizzino JohnEVP, CCO and CBOSep 20Sale227.577,5001,706,748718Sep 22 05:05 PM
Glenn Gregory MPresident, R&DSep 15Option Exercise37.901,18344,8325,244Sep 17 05:08 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 15Option Exercise19.085,00095,4005,706Sep 17 05:11 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 15Sale229.445,0001,147,193706Sep 17 05:11 PM
Glenn Gregory MPresident, R&DSep 15Sale229.341,183271,3044,061Sep 17 05:08 PM
Trizzino JohnEVP, CCO and CBOSep 14Option Exercise19.087,499143,0818,217Sep 15 05:03 PM
Trizzino JohnEVP, CCO and CBOSep 14Sale236.617,4991,774,360718Sep 15 05:03 PM
Trizzino JohnEVP, CCO and CBOSep 13Option Exercise19.087,499143,0818,217Sep 15 05:03 PM
Trizzino JohnEVP, CCO and CBOSep 13Sale235.297,4991,764,433718Sep 15 05:03 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 01Option Exercise19.085,00095,4005,706Sep 03 05:10 PM
Herrmann John A IIIEVP, Chief Legal OfficerSep 01Sale247.975,0001,239,867706Sep 03 05:10 PM
Glenn Gregory MPresident, R&DAug 31Sale239.871,386332,4634,061Sep 01 05:23 PM
Glenn Gregory MPresident, R&DAug 26Option Exercise5.956,92141,1808,228Aug 30 06:16 PM
Glenn Gregory MPresident, R&DAug 26Sale233.924,167974,7404,061Aug 30 06:16 PM
Glenn Gregory MPresident, R&DAug 16Option Exercise40.641,86675,8265,927Aug 18 05:26 PM
Glenn Gregory MPresident, R&DAug 16Sale233.521,866435,7504,061Aug 18 05:26 PM
Herrmann John A IIIEVP, Chief Legal OfficerJul 26Option Exercise14.832,89642,9603,602Jul 28 05:00 PM
Herrmann John A IIIEVP, Chief Legal OfficerJul 26Sale197.742,896572,648706Jul 28 05:00 PM
Glenn Gregory MPresident, R&DJul 20Sale215.432,409518,9822,811Jul 22 05:20 PM
Glenn Gregory MPresident, R&DJul 15Option Exercise13.0810,477137,0068,465Jul 19 07:52 PM
Glenn Gregory MPresident, R&DJul 15Sale179.455,6541,014,5972,811Jul 19 07:52 PM
Erck Stanley CPresident and CEOJul 02Option Exercise80.6652,5594,239,51173,054Jul 06 05:03 PM
Erck Stanley CPresident and CEOJul 02Sale215.8952,55911,347,06620,495Jul 06 05:03 PM
Erck Stanley CPresident and CEOJul 01Option Exercise61.5952,6203,240,96573,115Jul 06 05:03 PM
Erck Stanley CPresident and CEOJul 01Sale212.8852,62011,201,51320,495Jul 06 05:03 PM
Glenn Gregory MPresident, R&DJun 17Sale183.282,411441,8872,811Jun 17 06:17 PM
Glenn Gregory MPresident, R&DJun 15Option Exercise13.1610,535138,6858,527Jun 17 06:17 PM
Glenn Gregory MPresident, R&DJun 15Sale191.425,7161,094,1302,811Jun 17 06:17 PM
EVANS GARY CDirectorJun 01Sale146.5062591,5620Jun 03 05:34 PM
Herrmann John A IIIEVP, Chief Legal OfficerMay 28Option Exercise14.832,89542,9323,170Jun 02 04:59 PM
Herrmann John A IIIEVP, Chief Legal OfficerMay 28Sale149.142,895431,748275Jun 02 04:59 PM
King Rachel K.DirectorMay 19Buy139.6470097,7482,800May 21 05:06 PM
Glenn Gregory MPresident, R&DMay 19Sale142.172,385339,0662,811May 19 05:26 PM
Glenn Gregory MPresident, R&DMay 17Option Exercise13.1610,531138,5778,523May 19 05:26 PM
Glenn Gregory MPresident, R&DMay 17Sale133.985,712765,2672,811May 19 05:26 PM
Trizzino JohnEVP, CCO, CBO & Interim CFOMay 07Sale176.6319033,559287May 07 05:10 PM
Trizzino JohnEVP, CCO, CBO & Interim CFOMay 05Option Exercise14.733,40650,1603,309May 07 05:10 PM
Trizzino JohnEVP, CCO, CBO & Interim CFOMay 05Sale185.463,022560,471287May 07 05:10 PM
Herrmann John A IIIEVP, Chief Legal OfficerApr 30Option Exercise14.822,89542,8923,170May 04 06:03 PM